BR9610823A - Derivados de pirimidina como antagonistas do receptor - Google Patents
Derivados de pirimidina como antagonistas do receptorInfo
- Publication number
- BR9610823A BR9610823A BR9610823A BR9610823A BR9610823A BR 9610823 A BR9610823 A BR 9610823A BR 9610823 A BR9610823 A BR 9610823A BR 9610823 A BR9610823 A BR 9610823A BR 9610823 A BR9610823 A BR 9610823A
- Authority
- BR
- Brazil
- Prior art keywords
- receptor antagonists
- pyrimidine derivatives
- pyrimidine
- derivatives
- antagonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/84—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US473395P | 1995-10-02 | 1995-10-02 | |
PCT/EP1996/004099 WO1997012880A1 (en) | 1995-10-02 | 1996-09-19 | Pyrimidine derivatives as 5ht2c-receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9610823A true BR9610823A (pt) | 1999-07-13 |
Family
ID=21712250
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9610823A BR9610823A (pt) | 1995-10-02 | 1996-09-19 | Derivados de pirimidina como antagonistas do receptor |
Country Status (23)
Country | Link |
---|---|
US (1) | US5753663A (pt) |
EP (1) | EP0856001B1 (pt) |
JP (1) | JP3071830B2 (pt) |
KR (1) | KR100258052B1 (pt) |
CN (1) | CN1118460C (pt) |
AR (1) | AR004516A1 (pt) |
AT (1) | ATE222892T1 (pt) |
AU (1) | AU700637B2 (pt) |
BR (1) | BR9610823A (pt) |
CA (1) | CA2233003A1 (pt) |
CZ (1) | CZ98998A3 (pt) |
DE (1) | DE69623306T2 (pt) |
DK (1) | DK0856001T3 (pt) |
EA (1) | EA001311B1 (pt) |
ES (1) | ES2180798T3 (pt) |
HU (1) | HUP9802323A3 (pt) |
IL (1) | IL123581A (pt) |
MX (1) | MX9802383A (pt) |
NO (1) | NO310072B1 (pt) |
NZ (1) | NZ319158A (pt) |
PL (1) | PL326083A1 (pt) |
PT (1) | PT856001E (pt) |
WO (1) | WO1997012880A1 (pt) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9222253D0 (en) * | 1992-10-23 | 1992-12-09 | Celltech Ltd | Chemical compounds |
GB9304920D0 (en) * | 1993-03-10 | 1993-04-28 | Celltech Ltd | Chemical compounds |
GB9304919D0 (en) * | 1993-03-10 | 1993-04-28 | Celltech Ltd | Chemical compounds |
US5786354A (en) * | 1994-06-21 | 1998-07-28 | Celltech Therapeutics, Limited | Tri-substituted phenyl derivatives and processes for their preparation |
US6245774B1 (en) | 1994-06-21 | 2001-06-12 | Celltech Therapeutics Limited | Tri-substituted phenyl or pyridine derivatives |
GB9412573D0 (en) | 1994-06-22 | 1994-08-10 | Celltech Ltd | Chemical compounds |
GB9412571D0 (en) | 1994-06-22 | 1994-08-10 | Celltech Ltd | Chemical compounds |
JP3053222B2 (ja) * | 1995-04-20 | 2000-06-19 | ファイザー・インコーポレーテッド | Mmpおよびtnf抑制剤としてのアリールスルホニルヒドロキサム酸誘導体 |
GB9523675D0 (en) * | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
GB9619284D0 (en) * | 1996-09-16 | 1996-10-30 | Celltech Therapeutics Ltd | Chemical compounds |
GB9622363D0 (en) * | 1996-10-28 | 1997-01-08 | Celltech Therapeutics Ltd | Chemical compounds |
AU5330698A (en) | 1996-12-23 | 1998-07-17 | Celltech Therapeutics Limited | Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors |
GB9705361D0 (en) * | 1997-03-14 | 1997-04-30 | Celltech Therapeutics Ltd | Chemical compounds |
GB9713087D0 (en) * | 1997-06-20 | 1997-08-27 | Celltech Therapeutics Ltd | Chemical compounds |
GB9914258D0 (en) | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
GB9924862D0 (en) * | 1999-10-20 | 1999-12-22 | Celltech Therapeutics Ltd | Chemical compounds |
WO2001087845A2 (en) * | 2000-05-15 | 2001-11-22 | Fujisawa Pharmaceutical Co., Ltd. | N-containing heterocyclic compounds and their use as 5-ht antagonists |
IL159120A0 (en) * | 2001-05-29 | 2004-05-12 | Schering Ag | Cdk inhibiting pyrimidines, production thereof and their use as medicaments |
US7109337B2 (en) | 2002-12-20 | 2006-09-19 | Pfizer Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
GEP20084357B (en) | 2002-12-20 | 2008-04-29 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
UA80767C2 (en) * | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
CN1897950A (zh) * | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
WO2005111022A1 (en) | 2004-05-14 | 2005-11-24 | Pfizer Products Inc. | Pyrimidines derivatives for the treatment of abnormal cell growth |
BRPI0510963A (pt) | 2004-05-14 | 2007-11-20 | Pfizer Prod Inc | derivados pirimidina para o tratamento do crescimento anormal de células |
EP1756090A1 (en) | 2004-05-14 | 2007-02-28 | Pfizer Products Incorporated | Pyrimidine derivatives for the treatment of abnormal cell growth |
US20060205945A1 (en) * | 2004-05-14 | 2006-09-14 | Pfizer Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
CN101137381B (zh) * | 2005-03-15 | 2011-07-27 | 弗·哈夫曼-拉罗切有限公司 | 2-苯胺基-3,4-二氢-喹唑啉作为5ht5a受体拮抗剂的制药用途 |
WO2009081222A1 (en) | 2007-12-21 | 2009-07-02 | Glenmark Pharmaceuticals, S.A. | Substituted tricyclic pyridine or pyrimidine vanilloid receptor ligands |
ES2393694T3 (es) * | 2008-11-20 | 2012-12-27 | Merck Sharp & Dohme Corp. | Moduladores alostéricos positivos del receptor de aril metil benzoquinazolinona M1 |
US8357694B2 (en) * | 2008-12-30 | 2013-01-22 | Arqule, Inc. | Substituted 5,6-dihydro-6-phenylbenzo[F]isoquinolin-2-amine compounds |
WO2011075371A1 (en) * | 2009-12-14 | 2011-06-23 | Merck Sharp & Dohme Corp. | Pyridoquinazolinone m1 receptor positive allosteric modulators |
EP2515656B1 (en) * | 2009-12-21 | 2014-08-06 | Merck Sharp & Dohme Corp. | Aminobenzoquinazolinone m1 receptor positive allosteric modulators |
TWI402264B (zh) * | 2010-05-12 | 2013-07-21 | Merck Sharp & Dohme | 芳基甲基苯并喹唑啉酮m1受體之正向異位性調節劑 |
US8735386B2 (en) * | 2010-07-23 | 2014-05-27 | Boehringer Ingelheim International Gmbh | Aminopyrazoloquinazolines |
EP2790698A1 (en) | 2011-12-13 | 2014-10-22 | IO Therapeutics, Inc. | Autoimmune disorder treatment using rxr agonists |
CN103214489B (zh) * | 2013-02-25 | 2016-10-26 | 中国人民解放军第二军医大学 | 一类具有抗肿瘤活性的多靶点激酶抑制剂及其制备方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3177216A (en) * | 1961-12-28 | 1965-04-06 | Searle & Co | 4-trifluoromethyl-2-thio-5h-alka[d]-pyrimidines and congeners |
US3257400A (en) * | 1964-06-10 | 1966-06-21 | Searle & Co | 2-amino-5, 6-dihydrobenzo[h]quinazolin-4(3h)-one and congeners |
US3925384A (en) * | 1974-10-21 | 1975-12-09 | Squibb & Sons Inc | 2-Amino-4,5-dihydro-4-arylindeno pyrimidines |
EP0539170A1 (en) * | 1991-10-24 | 1993-04-28 | Merck Sharp & Dohme Ltd. | Benzodiazepine derivatives and their use as antagonists of cholecystokinin and/or gastrin receptors |
-
1996
- 1996-09-19 PL PL96326083A patent/PL326083A1/xx unknown
- 1996-09-19 PT PT96932569T patent/PT856001E/pt unknown
- 1996-09-19 DE DE69623306T patent/DE69623306T2/de not_active Expired - Fee Related
- 1996-09-19 MX MX9802383A patent/MX9802383A/es not_active IP Right Cessation
- 1996-09-19 HU HU9802323A patent/HUP9802323A3/hu unknown
- 1996-09-19 JP JP9513926A patent/JP3071830B2/ja not_active Expired - Fee Related
- 1996-09-19 IL IL12358196A patent/IL123581A/en not_active IP Right Cessation
- 1996-09-19 CA CA002233003A patent/CA2233003A1/en not_active Abandoned
- 1996-09-19 KR KR1019980702391A patent/KR100258052B1/ko not_active IP Right Cessation
- 1996-09-19 AU AU71311/96A patent/AU700637B2/en not_active Ceased
- 1996-09-19 NZ NZ319158A patent/NZ319158A/en unknown
- 1996-09-19 WO PCT/EP1996/004099 patent/WO1997012880A1/en not_active Application Discontinuation
- 1996-09-19 EA EA199800340A patent/EA001311B1/ru not_active IP Right Cessation
- 1996-09-19 EP EP96932569A patent/EP0856001B1/en not_active Expired - Lifetime
- 1996-09-19 CZ CZ98989A patent/CZ98998A3/cs unknown
- 1996-09-19 AT AT96932569T patent/ATE222892T1/de not_active IP Right Cessation
- 1996-09-19 ES ES96932569T patent/ES2180798T3/es not_active Expired - Lifetime
- 1996-09-19 BR BR9610823A patent/BR9610823A/pt not_active IP Right Cessation
- 1996-09-19 DK DK96932569T patent/DK0856001T3/da active
- 1996-09-19 CN CN96197385A patent/CN1118460C/zh not_active Expired - Fee Related
- 1996-09-24 US US08/719,062 patent/US5753663A/en not_active Expired - Fee Related
- 1996-10-01 AR ARP960104557A patent/AR004516A1/es unknown
-
1998
- 1998-04-01 NO NO981477A patent/NO310072B1/no unknown
Also Published As
Publication number | Publication date |
---|---|
JP3071830B2 (ja) | 2000-07-31 |
DE69623306T2 (de) | 2003-04-17 |
KR19990063918A (ko) | 1999-07-26 |
CN1198743A (zh) | 1998-11-11 |
AU700637B2 (en) | 1999-01-07 |
NO981477D0 (no) | 1998-04-01 |
US5753663A (en) | 1998-05-19 |
MX9802383A (es) | 1998-08-30 |
CZ98998A3 (cs) | 1998-10-14 |
NO981477L (no) | 1998-06-02 |
ATE222892T1 (de) | 2002-09-15 |
CA2233003A1 (en) | 1997-04-10 |
NZ319158A (en) | 1999-10-28 |
AR004516A1 (es) | 1998-12-16 |
EA001311B1 (ru) | 2001-02-26 |
AU7131196A (en) | 1997-04-28 |
PT856001E (pt) | 2003-01-31 |
EP0856001B1 (en) | 2002-08-28 |
DE69623306D1 (de) | 2002-10-02 |
DK0856001T3 (da) | 2002-12-30 |
PL326083A1 (en) | 1998-08-17 |
WO1997012880A1 (en) | 1997-04-10 |
EP0856001A1 (en) | 1998-08-05 |
EA199800340A1 (ru) | 1998-10-29 |
CN1118460C (zh) | 2003-08-20 |
HUP9802323A2 (hu) | 1999-03-29 |
HUP9802323A3 (en) | 1999-08-30 |
IL123581A (en) | 2001-09-13 |
ES2180798T3 (es) | 2003-02-16 |
IL123581A0 (en) | 1998-10-30 |
JPH10512288A (ja) | 1998-11-24 |
NO310072B1 (no) | 2001-05-14 |
KR100258052B1 (ko) | 2000-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9610823A (pt) | Derivados de pirimidina como antagonistas do receptor | |
BR9707391A (pt) | Pirazolpirimidinas como antagonistas de receptor de crf | |
NO972016D0 (no) | Indolyl-Y-reseptorantagonister | |
BR9612327A (pt) | Antagonistas receptores de vitronectina | |
PT1224175E (pt) | Derivados de benzodiazepina como antagonistas do receptor de glutamato metabotropico | |
IS5706A (is) | Adenosín A3 viðtakastillar | |
BR9612378A (pt) | Antagonistas receptores de vitronectina | |
DE69812096D1 (de) | Neuropeptid y rezeptorantagonisten | |
PT1224174E (pt) | Derivados de benzodiazepina como antagonistas do receptor metabotropico do glutamato | |
BR9508178A (pt) | Antagonistas de receptor de vitronectina | |
DE69734833D1 (de) | Vitronektin rezeptor antagonisten | |
FI960953A0 (fi) | Endoteliinireseptoriantagonisteja | |
ATE263151T1 (de) | Indolderivate verwendbar als endothelinrezeptorantagonisten | |
PT940391E (pt) | Derivados de quinolina como antagonistas do receptor de taquicinina nk3 | |
DE59712958D1 (de) | Substituierte Purinderivate als Vitronectinrezeptor-Antagonisten | |
ID16742A (id) | Antagonis reseptor endotelin | |
ID24726A (id) | Antagonis-antagonis reseptor trombin | |
PT861248E (pt) | Derivados indolealquilo de benzodioxanometilamina como ligandos do receptor 5-ht1a | |
ID24162A (id) | Antagonis-antagonis reseptor vitronektin | |
PT854867E (pt) | Tetra-hidroquinolinas como antagonistas de nmda | |
BR9507220A (pt) | Antagonistas de receptores de endotelina | |
BR9709982A (pt) | Derivados de indolina úteis como antagonistas do receptor 5-ht-2c | |
PT964863E (pt) | Oxazolidinonas como antagonistas de 5-ht2a | |
DZ2322A1 (fr) | Antagonistes de récepteurs de vitronectine. | |
BR9606668A (pt) | Piridazinonas como antagonista de receptor-endotelina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB36 | Technical and formal requirements: requirement - article 36 of industrial property law | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/01/2008, OBSERVADAS AS CONDICOES LEGAIS. |
|
B24C | Patent annual fee: request for for restoration |
Free format text: REFERENTE A 14A, 15A E 16A ANUIDADE(S), CONFORME ART. 87 DA LPI 9.279. |
|
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2184 DE 13/11/2012. |